[Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer].
A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer. The majority of patients was postmenopausal and pretreated with hormones and (or) chemotherapy. In 28 evaluable patients an overall objective response rate of 61% was achieved. Patients who received aminoglutethimide and polychemotherapy containing anthracyclines as FAC- or AV-regimen showed the highest objective response rate (67%). Thus, simultaneous combination of aminoglutethimide and polychemotherapy containing anthracycline derivatives is the most effective therapeutic regimen for those patients who were either pretreated or have progressive bone metastases with confinement to bed or have concomitant visceral metastases.
D000616:Aminoglutethimide / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000616:Aminoglutethimide; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Kombination von Aminoglutethimid und Polychemotherapie zur Behandlung von dominanter Knochenmetastasierung des Mammakarzinoms.